Editorial

. 2023 Sep 9;20(9):640-645.

doi: 10.20892/j.issn.2095-3941.2023.0211.

CSCO guidelines for metastatic colorectal cancer: personalized medicine in clinical practice

Mengyuan Yang^#¹, Ziheng Xu^#¹, Mi Mi¹, Yuwei Ding¹, Yuefen Pan², Ying Yuan^{1

3

4

5}, Weijing Sun⁶, Shanshan Weng^{1

3

4

5}

Affiliations

¹ Department of Medical Oncology (Key Laboratory of Cancer Prevention and Intervention, Chinese National Ministry of Education, Key Laboratory of Molecular Biology in Medical Sciences, Zhejiang Province, China), The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310009, China.
² Department of Medical Oncology, Huzhou Central Hospital, Huzhou 313000, China.
³ Zhejiang Provincial Clinical Research Center for Cancer, Hangzhou 310009, China.
⁴ Cancer Center of Zhejiang University, Hangzhou 310058, China.
⁵ Binjiang Institute of Zhejiang University, Hangzhou 310052, China.
⁶ Department of Medical Oncology, The University of Kansas, School of Medicine, Lawrence, KS 66045, United States.

^# Contributed equally.

PMID: 37700433
PMCID: PMC10546093
DOI: 10.20892/j.issn.2095-3941.2023.0211

Editorial

CSCO guidelines for metastatic colorectal cancer: personalized medicine in clinical practice

Mengyuan Yang et al. Cancer Biol Med. 2023.

. 2023 Sep 9;20(9):640-645.

doi: 10.20892/j.issn.2095-3941.2023.0211.

Authors

Mengyuan Yang^#¹, Ziheng Xu^#¹, Mi Mi¹, Yuwei Ding¹, Yuefen Pan², Ying Yuan^{1

3

4

5}, Weijing Sun⁶, Shanshan Weng^{1

3

4

5}

Affiliations

¹ Department of Medical Oncology (Key Laboratory of Cancer Prevention and Intervention, Chinese National Ministry of Education, Key Laboratory of Molecular Biology in Medical Sciences, Zhejiang Province, China), The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310009, China.
² Department of Medical Oncology, Huzhou Central Hospital, Huzhou 313000, China.
³ Zhejiang Provincial Clinical Research Center for Cancer, Hangzhou 310009, China.
⁴ Cancer Center of Zhejiang University, Hangzhou 310058, China.
⁵ Binjiang Institute of Zhejiang University, Hangzhou 310052, China.
⁶ Department of Medical Oncology, The University of Kansas, School of Medicine, Lawrence, KS 66045, United States.

^# Contributed equally.

PMID: 37700433
PMCID: PMC10546093
DOI: 10.20892/j.issn.2095-3941.2023.0211

No abstract available

PubMed Disclaimer

Conflict of interest statement

No potential conflicts of interest are disclosed.

Figures

**Figure 1**
A diagram summarizing CSCO guideline updates. The numbers in brackets represent the number of treatment lines recommended by the corresponding regimen. *Pembrolizumab, envafolimab, serplulimab, tislelizumab, and nivolumab + ipilimumab are preferred. ^&Trastuzumab + pertuzumab or trastuzumab + lapatinib are recommended.

See this image and copyright information in PMC

Cited by

Bioengineered Tumor-Derived Extracellular Vehicles Suppressed Colorectal Cancer Liver Metastasis and Bevacizumab Resistance.
Wang J, Liu C, Wang P, Liu Z, Hu W, Lv Z, Huang C, Yao X. Wang J, et al. Adv Sci (Weinh). 2025 Jun;12(23):e2417714. doi: 10.1002/advs.202417714. Epub 2025 May 21. Adv Sci (Weinh). 2025. PMID: 40397411 Free PMC article.
Ginsenosides: an immunomodulator for the treatment of colorectal cancer.
Qian J, Jiang Y, Hu H. Qian J, et al. Front Pharmacol. 2024 Jun 12;15:1408993. doi: 10.3389/fphar.2024.1408993. eCollection 2024. Front Pharmacol. 2024. PMID: 38939839 Free PMC article. Review.
Guidelines for Rational Clinical Use of Fentanyl Transdermal Patch.
Fu Q, Han N, Li N, Gui L, Shi C, Rong P, Zeng F, Rao H, Chen Y; Cancer Rehabilitation and Palliative Treatment Professional Committee of Hubei Anti Cancer Association. Fu Q, et al. Drug Des Devel Ther. 2024 Feb 1;18:233-255. doi: 10.2147/DDDT.S414318. eCollection 2024. Drug Des Devel Ther. 2024. PMID: 38362136 Free PMC article.

References

1. Zheng RS, Zhang SW, Sun KX, Chen R, Wang SM, Li L, et al. Cancer statistics in China, 2016. Zhonghua Zhong Liu Za Zhi. 2023;45:212–20. - PubMed
1. Jiang Y, Yuan H, Li Z, Ji X, Shen Q, Tuo J, et al. Global pattern and trends of colorectal cancer survival: a systematic review of population-based registration data. Cancer Biol Med. 2021;19:175–86. - PMC - PubMed
1. Biller LH, Schrag D. Diagnosis and treatment of metastatic colorectal cancer: a review. JAMA. 2021;325:669–85. - PubMed
1. Yao J, Zhen Y, Fan J, Gong Y, Ye Y, Guo S, et al. Comprehensive characterization of CRC with germline mutations reveals a distinct somatic mutational landscape and elevated cancer risk in the Chinese population. Cancer Biol Med. 2022;19:707–32. - PMC - PubMed
1. Dong C, Ding Y, Weng S, Li G, Huang Y, Hu H, et al. Update in version 2021 of CSCO guidelines for colorectal cancer from version 2020. Chinese J Cancer Res. 2021;33:302–7. - PMC - PubMed

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Europe PubMed Central
- PubMed Central
Medical
- MedlinePlus Health Information

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

CSCO guidelines for metastatic colorectal cancer: personalized medicine in clinical practice

Affiliations

CSCO guidelines for metastatic colorectal cancer: personalized medicine in clinical practice

Authors

Affiliations

Conflict of interest statement

Figures

Similar articles

Cited by

References

Publication types

MeSH terms

LinkOut - more resources

Full Text Sources

Medical